Cranberry (Poly)Phenol Consumption on Vascular Function
- Conditions
- Healthy Young
- Interventions
- Dietary Supplement: cranberry (poly)phenol containing supplement
- Registration Number
- NCT02764749
- Lead Sponsor
- Heinrich-Heine University, Duesseldorf
- Brief Summary
Epidemiological studies suggest that the consumption of (poly)phenols rich foods such as cocoa, tea, fruits and vegetables is associated with lower blood pressure, reduced cholesterol and decreased cardiovascular risk. Cranberries are a rich source of (poly)phenols, including anthocyanins, proanthocyanidins and phenolic acids. Whether cranberries can improve vascular function when given over relevant time periods and in relevant populations is not known. Therefore, it is the overall hypothesis of the study proposal that chronic consumption of cranberries can improve endothelial function, a prognostically validated surrogate of cardiovascular risk. This study also aims to reveal which cranberry (poly)phenols have bioactive properties in healthy men. Consequently, plasma and urine metabolite peaks will be correlated with vascular outcomes and genome-wide expression microarrays will be performed to reveal cell signaling pathways associated with cranberry (poly)phenol-mediated cardioprotective events.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 40
- healthy male subjects (no clinical signs or symptoms of CVD)
- Young >18 years, <35 years
- CVD
- acute inflammation
- cardiac arrhythmia
- renal failure
- heart failure (NYHA II-IV)
- diabetes mellitus
- CRP > 1 mg/dl
- malignant disease
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description freeze dried powder whole cranberry dissolved in water cranberry (poly)phenol containing supplement Dietary Supplement: freeze dried cranberry powder
- Primary Outcome Measures
Name Time Method Change form Baseline Endothelial function at 1 month 2 hours and 1 month Measured by Flow mediated dilation (FMD)
- Secondary Outcome Measures
Name Time Method Pulse wave velocity Baseline and 1 month Measured by SphygmoCor 0 and 2 hours postconsumption
Blood pressure Baseline and 1month automatical measurements 0 and 2 hours postconsumption
high density lipoproteins (HDL) Baseline and 1 month measured on baseline and after 1 month
low density lipoproteins (LDL) Baseline and 1 month measured on baseline and after 1 month
triglyceride Baseline and 1 month measured on baseline and after 1 month
Trial Locations
- Locations (1)
Division of Cardiology, Pulmonary Disease and Vascular Medicine, University Hospital Duesseldorf
🇩🇪Duesseldorf, Germany